

Swelife ATMP SDP4 – Gene Therapy





Participants



Karolinska
Institutet





Challenge to address:

“Identify opportunities and challenges for Sweden to become internationally leading in the field of gene therapy.”



Implementation

What and how we did it

Workshop 2018 ► Web meetings 2019 ► Topic ► Report ► Presentation 2020

3(3)

SWOT analysis of Gene Therapy in Sweden

Assumption: analysis is based on Sweden as a gene therapy country

Strengths <ul style="list-style-type: none">• Good basic research and technological environment• Short time from "bench to bedside"• Long tradition of technology acceptance in health care• Fair financial resourcing (tax based) in health care and research• Patient registries (Kvalitetsregister)• "Dare to try" mentality	Weaknesses <ul style="list-style-type: none">• Funding too spread out. Too many small projects are funded, no focus on few spearhead projects• Weak incubator tradition• Lack of production facilities for clinical trials• Small patient population• Research lacks national coordination• Pharma industry not visible in research environment• Healthcare too top-down (run by politicians)
Opportunities <ul style="list-style-type: none">• CAMP as national coordinator/hub• This is the right time to make ourselves visible "momentum"• Good relations with authorities (LV, TLV, EMA)• High know-how/competence	Threats <ul style="list-style-type: none">• Loss of competence because trials are not run in Sweden• "Brain-drain" to other tech areas/countries• Underfinancing of SME/start-ups• Too few biotech companies to create a "snowball effect"• GT technology too expensive for such a small country• Safety [Nb. Not sure what this comment meant]



Lack of production facilities



What was the additional value of doing the work within Swelife ATMP?

- Collective experience
- Brainstorming
- Sharing challenges and ideas
- Synergies from previous work in gene therapy
- Focus ideas



Results and effects

Deliverables


Report: *Manufacturing of Gene Therapy Products: A Swedish Perspective*
Presentation

Unexpected results or effects?

- + Successful technology can be hampered by a manufacturing bottleneck
- Gene therapy is a heterogeneous field



How did the work and deliverables increase Sweden's competitiveness in the ATMP field?





Conclusions and reflections

Learnings, if we did it again what would we do differently?

- Identify "threats" to project and workflow
 - Literature review
 - Core group assignments

What worked well?

- Team spirit – reach the goal
- Shared experiences
- Collaboration & coaching



Forwards, future?

What happens now?

Are there certain niches that Sweden could/should focus on?

Thank You



AstraZeneca

- John Wiseman

CombiGene

- Karin Agerman

GE Healthcare

- Margareta Tennander
- Daria Donati

Karolinska Institutet

- Edward Smith
- Matti Sällberg

Karolinska Centrum f. cellterapi

- Kristina Kannisto
- Pontus Blomberg

Pfizer

- Christian Gerdesköld

RISE

- Linnea Enstedt
- Jim Lund
- Per Wessman